INTRODUCTION: The present research aimed to determine the relation between the use of angiotensin-converting enzyme inhibitors (ACE inh) and angiotensinogen receptor blockers (ARBs) and in-hospital mortality of hypertensive patients diagnosed with Covid-19 pneumonia. MATERIAL AND METHOD: In this retrospective study, we included 113 consecutive hypertensive patients admitted due to Covid-19 infection. In all patients, Covid-19 infection was confirmed with using reverse-transcription polymerase chain reaction. All patients were on ACE inh/ARBs or other antihypertensive therapy unless no contraindication was present. The primary outcome of the study was the in-hospital all-cause mortality. RESULTS: In total, 113 hypertensive Covid-19 patients were included, of them 74 patients were using ACE inh/ARBs. During in-hospital follow up, 30.9% [n = 35 patients] of patients died. The frequency of admission to the ICU and endotracheal intubation were significantly higher in patients using ACE inh/ARBs. In a multivariable analysis, the use of ACE inh/ARBs was an independent predictor of in-hospital mortality (OR: 3.66; 95%CI: 1.11-18.18; p= .032). Kaplan-Meir curve analysis displayed that patients on ACE inh/ARBs therapy had higher incidence of in-hospital death than those who were not. CONCLUSION: The present study has found that the use of ACE inh/ARBs therapy might be associated with an increased in-hospital mortality in patients who were diagnosed with Covid-19 pneumonia. It is likely that ACE inh/ARBs therapy might not be beneficial in the subgroup of hypertensive Covid-19 patients despite the fact that there might be the possibility of some unmeasured residual confounders to affect the results of the study.
INTRODUCTION: The present research aimed to determine the relation between the use of angiotensin-converting enzyme inhibitors (ACE inh) and angiotensinogen receptor blockers (ARBs) and in-hospital mortality of hypertensivepatients diagnosed with Covid-19 pneumonia. MATERIAL AND METHOD: In this retrospective study, we included 113 consecutive hypertensivepatients admitted due to Covid-19infection. In all patients, Covid-19infection was confirmed with using reverse-transcription polymerase chain reaction. All patients were on ACE inh/ARBs or other antihypertensive therapy unless no contraindication was present. The primary outcome of the study was the in-hospital all-cause mortality. RESULTS: In total, 113 hypertensiveCovid-19patients were included, of them 74 patients were using ACE inh/ARBs. During in-hospital follow up, 30.9% [n = 35 patients] of patientsdied. The frequency of admission to the ICU and endotracheal intubation were significantly higher in patients using ACE inh/ARBs. In a multivariable analysis, the use of ACE inh/ARBs was an independent predictor of in-hospital mortality (OR: 3.66; 95%CI: 1.11-18.18; p= .032). Kaplan-Meir curve analysis displayed that patients on ACE inh/ARBs therapy had higher incidence of in-hospital death than those who were not. CONCLUSION: The present study has found that the use of ACE inh/ARBs therapy might be associated with an increased in-hospital mortality in patients who were diagnosed with Covid-19 pneumonia. It is likely that ACE inh/ARBs therapy might not be beneficial in the subgroup of hypertensiveCovid-19patients despite the fact that there might be the possibility of some unmeasured residual confounders to affect the results of the study.
Authors: Terry Lee; Alessandro Cau; Matthew Pellan Cheng; Adeera Levin; Todd C Lee; Donald C Vinh; Francois Lamontagne; Joel Singer; Keith R Walley; Srinivas Murthy; David Patrick; Oleksa G Rewa; Brent W Winston; John Marshall; John Boyd; Karen Tran; Andre C Kalil; Russell Mcculoh; Robert Fowler; James M Luther; James A Russell Journal: CJC Open Date: 2021-04-06
Authors: Diogo Turiani Hourneaux de Moura; Igor Mendonça Proença; Thomas R McCarty; Vitor Massaro Takamatsu Sagae; Igor Braga Ribeiro; Guilherme Henrique Peixoto de Oliveira; Gabriel Mayo Vieira de Souza; Bruno Salomão Hirsch; Maria Vitória Cury Vieira Scatimburgo; Christopher C Thompson; Flair José Carrilho; Ivan Cecconello; Eduardo Guimarães Hourneaux de Moura Journal: Clinics (Sao Paulo) Date: 2020-10-26 Impact factor: 2.365